SCHEMBL4479123

SCHEMBL4479123

[CH2]CC(O)c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.45
SLC6A4 P31645 2/20 0.45
SLC6A3 Q01959 1/20 0.45
KDM4E B2RXH2 2/20 0.44
TSHR P16473 1/20 0.44
TP53 P04637 1/20 0.42
KCNA5 P22460 7/20 0.42
KCNH2 Q12809 1/20 0.42
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
IDO1 P14902 1/20 0.40
KCNE1 P15382 2/20 0.40
MAPT P10636 1/20 0.40
CYP2D6 P10635 2/20 0.40
NPSR1 Q6W5P4 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
SCN5A Q14524 1/20 0.39
KCND3 Q9UK17 1/20 0.39
CHRM2 P08172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30910020 0.83 SLC6A2 (0.48) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL5789944 0.82 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL8922337 0.81 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL29767197 0.81 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL6481541 0.81 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL31744336 0.81 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL30663811 0.81 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL506917 0.81 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL7268370 0.81 KCNA5 (0.52) SLC6A2SLC6A4SLC6A3KDM4ETSHR
SCHEMBL211788 0.81 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KDM4ETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 US claimed
US-7625909-B2 Substituted quinazolinone compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2009-12-01 US disclosed
CN-1235870-C Novel use of phenyl hetero alkylamine derivatives ASTRAZENECA AB (SE) 2006-01-11 CN disclosed
US-20050059662-A1 Substituted quinazolinone compounds CHIRON CORPORATION 2005-03-17 US disclosed
CN-1411435-A Novel use of phenylheteroalkylamine derivatives ASTRAZENECA AB (SE) 2003-04-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059662-A1 Substituted quinazolinone compounds MC4R, MC2R, MC3R SLC6A2 1389/4885SLC6A4 248/4885SLC6A3 1108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.